TCL-309: Prognostic Role of CD30 From a Retrospective Review of 295 Patients with Angioimmunoblastic T-Cell Lymphoma

Shehab Mohamed,Julia Parrish,Maliha Khan,Sarah Premji,Alexander Elias,Luis Malpica,Ranjit Nair,Dai Chihara,Samer Srour,Roberto Miranda,Jie Xu,Francisco Vega,Sawminathan Iyer

DOI: https://doi.org/10.1016/s2152-2650(21)01930-3

2021-01-01

Abstract:Objective The main aim of this single-institution retrospective study was to elucidate the prognostic significance of CD30 expression in AITL. Methods We analyzed patients newly diagnosed with AITL at our institution between 2000 and 2020. Along with CD30 receptor testing, variables, including date of diagnosis, age, gender, stage, LDH level, platelets, hemoglobin, bone marrow involvement, and EBV receptor positivity, were collected. Treatment and progression data, including response to frontline therapy, presence of consolidation stem cell transplant (SCT), and usage of brentuximab-based treatment, were collected. Endpoints were progression-free survival (PFS) and OS. Univariate (UVA) and multivariate (MVA) Cox proportional hazard models were used to determine the significance of variables at diagnosis on PFS and OS. Results Out of the 295 individuals diagnosed with AITL, 129 patients with CD30 testing who had both response and survival data were included. This group had a median age of 65 (range 29–83) years and a male predominance (51%). Median follow-up time was 40 (range 2–137) months, with three-year PFS and OS of 48% and 23%, respectively. Sixty-seven individuals died within the first three years of the study. The 3-year OS is 46% in CD30+ individuals and 55% in those who are CD30– (p=0.578). PFS is 20% in CD30+ individuals and 29% in those who are CD30– (p=0.675). SCT (p=0.0003) was statistically associated with improved survival. For OS, age >65 (HR: 3.131, 95%CI: 1.545–6.344, p=0.0015), BM involvement (HR: 2.134, 95% CI: 1.151–3.956, p=0.0161), incomplete remission (HR: 2.208, 95% CI: 1–4.876, p=0.0499), male gender (HR: 0.367, 95% CI: 0.199–0.678, p=0.0014), no SCT (HR: 4.085, 95% CI: 2.119–7.872, p≤0.0001), and positive CD30 (HR: 0.322, 95% CI: 0.158–0.656, p=0.0018) were associated with inferior OS. Conclusion Age <65, achieving CR to induction treatment, and upfront SCT proved to be strong predictors of improved OS. In our cohort, only 20% of patients received BV; nevertheless, unlike previous studies, individuals with CD30 positivity did not trend towards better OS. Therefore, additional work on CD30 biology in AITL is warranted. The main aim of this single-institution retrospective study was to elucidate the prognostic significance of CD30 expression in AITL. We analyzed patients newly diagnosed with AITL at our institution between 2000 and 2020. Along with CD30 receptor testing, variables, including date of diagnosis, age, gender, stage, LDH level, platelets, hemoglobin, bone marrow involvement, and EBV receptor positivity, were collected. Treatment and progression data, including response to frontline therapy, presence of consolidation stem cell transplant (SCT), and usage of brentuximab-based treatment, were collected. Endpoints were progression-free survival (PFS) and OS. Univariate (UVA) and multivariate (MVA) Cox proportional hazard models were used to determine the significance of variables at diagnosis on PFS and OS. Out of the 295 individuals diagnosed with AITL, 129 patients with CD30 testing who had both response and survival data were included. This group had a median age of 65 (range 29–83) years and a male predominance (51%). Median follow-up time was 40 (range 2–137) months, with three-year PFS and OS of 48% and 23%, respectively. Sixty-seven individuals died within the first three years of the study. The 3-year OS is 46% in CD30+ individuals and 55% in those who are CD30– (p=0.578). PFS is 20% in CD30+ individuals and 29% in those who are CD30– (p=0.675). SCT (p=0.0003) was statistically associated with improved survival. For OS, age >65 (HR: 3.131, 95%CI: 1.545–6.344, p=0.0015), BM involvement (HR: 2.134, 95% CI: 1.151–3.956, p=0.0161), incomplete remission (HR: 2.208, 95% CI: 1–4.876, p=0.0499), male gender (HR: 0.367, 95% CI: 0.199–0.678, p=0.0014), no SCT (HR: 4.085, 95% CI: 2.119–7.872, p≤0.0001), and positive CD30 (HR: 0.322, 95% CI: 0.158–0.656, p=0.0018) were associated with inferior OS. Age <65, achieving CR to induction treatment, and upfront SCT proved to be strong predictors of improved OS. In our cohort, only 20% of patients received BV; nevertheless, unlike previous studies, individuals with CD30 positivity did not trend towards better OS. Therefore, additional work on CD30 biology in AITL is warranted.